

Book by 18th December 2009 to receive a £100 early bird discount

SMi presents its inaugural conference on...

Pharmacovigilance

Systems for Drug Development & Post-Marketing Surveillance

Monday 15th and Tuesday 16th March 2010
Crowne Plaza London - St. James

KEY SPEAKERS INCLUDE:

Andrew P. Marr
Director, Global e-Regulatory Development, Global Regulatory Operations
GlaxoSmithKline

Sian Ratcliffe
Senior Director, Safety and Risk Management Lead
Pfizer

Jacques Wodelet
Head of Quality Intelligence
Merck Serono

Leann Fieldstad
Global Head of Compliance
F. Hoffmann-La Roche

Dominique Brunier
Head of Pharmacovigilance and Quality, Europe
Novartis

Benoit Nauge
Senior Manager, Global Compliance Auditing
Amgen

Ceri Deveney
Director, Pharmacovigilance
MedImmune

KEY TOPICS:

- Pharmacovigilance system design
- Post-marketing drug safety and risk management
- The future of pharmacovigilance in the EU
- Handling inspections by national health authorities
- Development of an internal audit strategy



Conference highlights include presentations on inspections, risk management, the use of Independent Data Monitoring Committees and managing relationships with regulatory bodies

SPONSORED BY:



PLUS A HALF DAY POST-CONFERENCE WORKSHOP

Wednesday 17th March 2010, Crowne Plaza London - St. James

Pharmacovigilance Inspections: a Practical Approach

Workshop leader: **Colin Knight**, Senior Partner, **Transcrip Partners**

8.30am - 12.30pm

www.smi-online.co.uk/pharmacovigilance.asp

Register online and receive full information on all of SMi's conferences

Alternatively fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711



8.30 Registration & Coffee

9.00 **Chairman's opening remarks**

William C. Maier, Vice President, Epidemiology, Drug Safety and Risk Management, **Registrot-Mapi**

9.10 **OPTIMISING PHYSICIANS AND HEALTHCARE PROFESSIONALS IN GLOBAL PHARMACOVIGILANCE**

- A vital colleague accountable for the medical cohesiveness of ICSRs
- Providing clinical judgment to colleagues responsible for case processing activities
- Understanding the product profile and actively supporting safety teams
- Establishing a collaborative environment between safety operations, safety science and clinical science
- Safety physicians role in leading the risk management activities

Leann Fieldstad, Global Head of Compliance, **F. Hoffmann-La Roche**

9.50 **POST-MARKETING DRUG SAFETY AND RISK MANAGEMENT – THE NEW REALITY**

- Regulatory requirements and strategic considerations
- Signal generation – case investigation, trials, spontaneous events, databases, data mining
- Signal investigation – study designs and resources
- Comparison of methods used at different stages of drug development
- Risk management planning – US/EU regulations, tools and strategy

William C. Maier, Vice President, Epidemiology, Drug Safety and Risk Management, **Registrot-Mapi**

10.30 Morning Coffee

11.00 **THE ICH INDIVIDUAL CASE SAFETY REPORT SIGNIFICANT CHANGES AHEAD: WHY AND HOW?**

- Transition of the ICH standard from 'home-grown' to an international standard
- Rationale for the change - collaboration with HL7/ISO/CEN
- Changes anticipated and associated timelines

Andrew P. Marr, Director, Global e-Regulatory Development, Global Regulatory Operations, **GlaxoSmithKline**

11.40 **SAFETY SPECIFICATION AND RISK MANAGEMENT: THE ROLE OF THE RESEARCHER**

- How to develop safety specification and identify issues and missing information
- The role of drug utilisation studies to support risk management
- Pharmacoepidemiological studies
- Monitoring the effectiveness of risk management
- Case studies

Saad Shakir, Director, **The Drug Safety Research Unit**

12.20 Networking Lunch

1.50 **THE FUTURE OF PHARMACOVIGILANCE IN THE EU**

Key issues of European Commission proposal on pharmacovigilance

- The new Pharmacovigilance Risk Assessment Advisory Committee (PRAAC)
- New expedited reporting requirements
- New requirements on PSURs
- Summary of essential information

Elmar Kroth, Head of Pharmacovigilance, **German Medicines Manufacturers' Association**

2.30 **SUCCESSFUL PHARMACOVIGILANCE AND GCP INSPECTIONS**

- Inspections – what and why?
- Effective preparation before the inspection
- Logistics and planning – how to be ready
- During the inspection – how to survive and perform

Ceri Deveney, Director, Pharmacovigilance, **MedImmune**

3.10 Afternoon Tea

3.40 **INTERNAL AUDIT STRATEGY FOR PHARMACOVIGILANCE**

- How to define and maintain the audit universe
- The risk-based approach in practice
- Creating and validating the audit plan
- Implementing the audit plan

Benoit Nauge, Senior Manager, Global Compliance Auditing, **Amgen**

4.20 **DRUG SAFETY: A VIEW FROM A PHARMACOVIGILANCE REGIONAL CENTRE**

- Spontaneous reporting
- Signal follow-up
- Case/non-case approach
- Causality reasoning in pharmacovigilance

Alfonso Carvajal, Professor of Pharmacology, Institute of Pharmacoepidemiology, **University of Valladolid**

5.00 **Chairman's Closing Remarks and Close of Day One**

Register online at www.smi-online.co.uk/pharmacovigilance.asp • Altern

Sponsored by



TranScript Partners is a partnership of pharmaceutical professionals offering a wide range of expertise in drug development and commercialisation. Their team consists of highly skilled, experienced senior partners and partners supported by associates working across a wide range of pharmaceutical sub-disciplines and therapeutic areas. TranScript Partners have a powerful commitment to lasting high performance through the continuity of the partnership. www.transcrip-partners.com

Supported by

8.30 Re-registration & Coffee

9.00 **Chairman's opening remarks**

Ralph Edwards, Medical Advisor, **Uppsala Monitoring Centre**

9.10 **PHARMACOVIGILANCE INSPECTIONS BY NATIONAL HEALTH AUTHORITIES**

- Challenges for the industry
- Organisation and key tasks
- Need for sustained readiness
- Inspection process and outcome

Dominique Brunier, Head of Pharmacovigilance and Quality, Europe **Novartis**

9.50 **DEVELOPING A PROACTIVE APPROACH TOWARD INSPECTIONS**

- Inspection objectives
- Visual thinking and process mapping
- Categories of individuals
- Inspection readiness
- Technical and financial aspects

Jacques Wodelet, Head of Quality Intelligence, **Merck Serono**

10.30 Morning Coffee

11.00 **QUALITY MANAGEMENT SYSTEMS IN PHARMACOVIGILANCE**

- What system should be in place to support pharmacovigilance legislation and guidelines?
- Essential features of a robust quality management system
- Quality oversight at both a global and local marketing affiliate level
- Internal audits of a pharmacovigilance system

Lucy Hampshire, Quality Consultant, **Eli Lilly**

11.40 **DRUG SAFETY IN THE CONTEXT OF CLINICAL TRIALS**

Independent Data Monitoring Committees and randomised trials in phase IV

- Importance of IDMC make-up and charter
- Roles of IDMCs in phases I/II/III
- Optimising IDMC reports
- Potential for low-cost large randomised drug safety trials in phase IV

Ian Ford, Director, **Robertson Centre for Biostatistics**

12.20 Networking Lunch

1.50 **CASE STUDY: THE DESIGN AND IMPLEMENTATION OF A PHARMACOVIGILANCE SYSTEM IN A MULTINATIONAL EUROPEAN COMPANY**

- Legal background
- Implementation of a pharmacovigilance system in a small European company
- Increasing efficiency in a standardised global pharmacovigilance process
- What worked well
- Opportunities for improvement

Petra Heyen, Vice President, Regulatory Affairs and Pharmacovigilance, **Therabel Pharma**

2.30 **OPTIMISING THE BENEFIT/RISK PROFILE WITH EFFECTIVE RISK MANAGEMENT PLANNING THROUGHOUT DRUG DEVELOPMENT**

- Risk prediction in early development
- Risk identification and mitigation in mid and late development
- Safety review/analysis plans
- Regulatory expectations and interactions, REMS and RMPs

Sian Ratcliffe, Senior Director, Safety and Risk Management Lead, **Pfizer**

3.10 Afternoon Tea

3.40 **FINDING THE WOOD AMONGST THE TREES – HOW TO EVALUATE A POTENTIAL SAFETY SIGNAL**

- Whether a signal is real or not
- Including the Bradford Hill Criteria
- Graphical representations of data
- Making a decision

Nicky Wallis, Medical Director, Oncology, **Pfizer**

4.20 **CIOMS VIII: SIGNALS AND BEYOND**

- Role of Council for Organisations of Medical Sciences
- Impending publication of CIOMS VIII
- Data-mining of longitudinal health care records
- Risks and benefits

Ralph Edwards, Medical Advisor, **Uppsala Monitoring Centre**

5.00 **Chairman's Closing Remarks and Close of Conference**

actively fax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711

Who should attend this event?

All those responsible for pharmacovigilance in the following areas:

- Post-marketing
- Regulatory Affairs
- Risk Management
- Quality Assurance
- Compliance

Why you should attend:

- Hear the latest updates on pharmacovigilance systems in the industry
- Explore ways in which you can optimise your own pharmacovigilance activities
- Discuss the potential impact of impending regulatory changes
- Learn more about the relationship between drug safety and pharmacovigilance

SPONSORSHIP AND EXHIBITION OPPORTUNITIES

SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company's marketing strategy. Should you wish to join the increasing number of companies benefitting from sponsoring our conferences please call: Alia Malick on +44 (0)20 7827 6168 or email: amalick@smi-online.co.uk

Want to know how you can get involved? Interested in promoting your pharmaceutical services to this market? Contact Margaret Mugema, SMi Marketing on +44 (0) 20 7827 6072 or email: mmugema@smi-online.co.uk

PHARMACEUTICAL FORWARD PLANNER

JANUARY 2010

- 18/19 Paediatric Clinical Trials
- 18/19 Models for Key Opinion Leader Management*
- 20/21 Pre-filled Syringes
- 27/28 Electronic Laboratory Notebooks

FEBRUARY 2010

- 01/02 Biomarkers Summit
- 03/04 Adaptive Designs in Clinical Drug Development
- 10/11 Parallel Trade
- 15/16 Stem Cells
- 22/23 Drug Design

MARCH 2010

- 10/11 Imaging in Oncology
- 15/16 Pharmacovigilance
- 17/18 Superbugs & Superdrugs
- 24/25 Accelerating Patient Recruitment in Clinical Trials

APRIL 2010

- 21/22 Asthma & COPD
- 21/22 Computer Systems Validation
- 26/27 High Throughput Screening
- 28/29 Controlled Release

MAY 2010

- 10/11 Generics, Supergenerics & Patient Strategies
- 17/18 Clinical Trial Logistics

JUNE 2010

- 07/08 Pain Therapeutics
- 14/15 KOL Europe*
- 17/18 Global Protein Summit
- 28/29 RNAi, siRNA & miRNA
- 28/29 Pharmaceutical Portfolio & Product Lifecycle Management

JULY 2010

- 05/06 Clinical Trials in Cancer
- 06/07 ADMET
- 12/13 In Vitro Diagnostics

* These conferences will take place in mainland Europe.

ABOUT THE SMI PHARMACEUTICAL TEAM

SMi have been involved in the pharmaceutical industry since 1993 and have developed a series of informative and niche events, covering the latest issues and developments surrounding the industry. Events bring together senior industry professionals and serving companies who have a focus on being at the forefront of developments in this area. SMi aim to generate informed and topical discussion through the medium of both conferences and executive briefings. Our pharmaceutical events are research-based and content driven with regular contact with major industry personnel and cover a wide range of industry sectors. For more information, please visit www.smi-online.co.uk/pharma.asp

**Want to know how you can get involved?
Interested in promoting your
pharmaceutical services to this market?**

Contact Margaret Mugema, SMi Marketing
on +44 (0) 20 7827 6072 or
email: mmugema@smi-online.co.uk

Pharmacovigilance Inspections: a Practical Approach

In association with: TranScrip Partners

This is a practical workshop aimed at all personnel involved in PV inspections. It will cover the concept of inspection readiness not just for the PV department but for the entire company; before, during and after the inspection. Topics that will be covered include logistics, communication (both internal and external), document preparation and interview preparation. We will introduce handy tools and processes to aid inspection management.

Workshop Agenda:

- [Introduction to inspection readiness](#)
- [Tools for managing PV inspections](#)
- [Inspection do's and don'ts](#)
- [Interview preparation](#)

8.30 [Registration & Coffee](#)

9.00 [Introduction and ice-breaker](#)

9.30 [Preparing for the inspection](#)

10.30 [Coffee](#)

10.50 [Managing the inspection](#)

11.30 [Exercise](#)

12.00 [After the inspection](#)

12.20 [Questions](#)

12.30 [Close of Workshop](#)

About the Workshop Leader:



Colin Knight is a pharmacovigilance scientist with over 30 years of varied industry experience in different therapeutic areas including CNS, ophthalmology, wound-healing and pain.

At AstraZeneca Colin was responsible for providing pharmacovigilance input into global study teams. More recently, he worked with a global team involved with the development of an in-house safety database. In addition, he has direct experience of converting legacy safety data from several coding dictionaries into the MedDRA dictionary. Colin has a special interest in Data Safety Monitoring Boards (DSMB) and has given external presentations on industry perspectives of DSMB at academic meetings.

PHARMACOVIGILANCE

Conference: Monday 15th and Tuesday 16th March 2010, Crowne Plaza London - St. James Workshops: Wednesday 17th March 2010, London

4 WAYS TO REGISTER

www.smi-online.co.uk/pharmacovigilance.asp

FAX your booking form to +44 (0) 870 9090 712

PHONE on +44 (0) 870 9090 711

POST your booking form to: Events Team, SMi Group Ltd, Great Guildford Business Square, 30 Great Guildford Street London, SE1 0HS, UK

--	--

Unique Reference Number	
Our Reference	LVU69

DELEGATE DETAILS

Please complete fully and clearly in capital letters. Please photocopy for additional delegates.

Title: Forename: _____

Surname: _____

Job Title: _____

Department/Division: _____

Company/Organisation: _____

Email: _____

Address: _____

Town/City: _____

Post/Zip Code: Country: _____

Direct Tel: Direct Fax: _____

Mobile: _____

Switchboard: _____

Signature: Date: _____

I agree to be bound by SMi's Terms and Conditions of Booking.

ACCOUNTS DEPT

Title: Forename: _____

Surname: _____

Email: _____

Address (if different from above): _____

Town/City: _____

Post/Zip Code: Country: _____

Direct Tel: Direct Fax: _____

Terms and Conditions of Booking

Payment: If payment is not made at the time of booking, then an invoice will be issued and must be paid immediately and prior to the start of the event. If payment has not been received then credit card details will be requested before entry to the event. CD ROMs will not be despatched until payment has been received.

Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another delegate to take your place at any time prior to the start of the event. Two or more delegates may not 'share' a place at an event. Please make separate bookings for each delegate.

Cancellation: If you wish to cancel your attendance at a Conference and/or Briefing and you are unable to send a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing that cancellation is made in writing and received at least 28 days prior to the start of the event. Regrettably cancellation after this time cannot be accepted. We will however provide the Conference documentation on CD ROM to any delegate who has paid but is unable to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to provide documentation in these circumstances. We cannot accept cancellations of orders placed for Documentation or CD ROM as these are reproduced specifically to order. If we have to cancel the event for any reason, then we will make a full refund immediately, but disclaim any further liability.

Alterations: It may become necessary for us to make alterations to the content, speakers, timing, venue or date of the event compared to the advertised programme.

Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other products and services. Unless you tick here we may also share your data with third parties offering complementary products or services. If you have any queries or want to update any of the data that we hold then please contact our Database Manager databasemanager@smi-online.co.uk or visit our website www.smi-online.co.uk/updates quoting the URN as detailed above your address on the attached letter.

EARLY BIRD DISCOUNT

Book by 18th December to receive £100 off conference price

CONFERENCE PRICES

I would like to attend: (Please tick as appropriate)	Fee	Total
<input type="checkbox"/> Conference and Half Day Workshop	£1798.00 + VAT	£2067.70
<input type="checkbox"/> Conference only	£1299.00 + VAT	£1493.85
<input type="checkbox"/> Half Day Workshop only	£499.00 + VAT	£573.85

PROMOTIONAL LITERATURE DISTRIBUTION

<input type="checkbox"/> Distribution of your company's promotional literature to all conference attendees	£999.00 + VAT	£1148.85
--	---------------	----------

GROUP DISCOUNTS AVAILABLE

The Conference fee includes refreshments, lunch, conference papers and CD ROM containing all of the presentations.

VENUE Crowne Plaza St James, Buckingham Gate, London SW1E 6AF

Please contact me to book my hotel

Alternatively call us on +44 (0) 870 9090 711, email: hotels@smi-online.co.uk or fax +44 (0) 870 9090 712

CD ROMS/DOCUMENTATION

I cannot attend but would like to purchase the following CD ROMs/paper copy documentation: (Shipped 10-14 days after the event)	Price	Total
<input type="checkbox"/> The Conference Presentations on CD ROM	£499.00 + VAT	£573.85
<input type="checkbox"/> The Conference Presentations - paper copy (or only £300 if ordered with a CD ROM)	£499.00 -	£499.00

PAYMENT

Payment must be made to **SMi Group Ltd**, and received before the event, by one of the following methods **quoting reference U69 and the delegate's name**. Bookings within 7 days of event requires a credit card as guarantee. Please indicate method of payment:

- UK BACS** Sort Code 300009, Account 00936418
- Wire Transfer** Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
IBAN GB48 LOYD 3000 0900 9364 18
- Cheque** We can only accept Sterling cheques drawn on a UK bank.
- Credit Card** Visa MasterCard American Express

All credit card payments will be subject to standard credit card charges.

Card No:

Valid From / Expiry Date /

CVV Number 3 digit security on reverse of card, 4 digits for AMEX card

Cardholder's Name: _____

Signature: _____

Date: _____

I agree to be bound by SMi's Terms and Conditions of Booking.

Card Billing Address (If different from above): _____

VAT

VAT at 15% is charged on the attendance fees for all delegates. VAT is also charged on CD ROMs and Literature Distribution for all UK customers and for those EU customers not supplying a registration number for their own country here: _____